Palvella Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
17
- Latest Deal Type
-
PIPE
- (Announced)
- Latest Deal Amount
-
$78.9M
- Investors
-
6
Palvella Therapeutics General Information
Description
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.
Contact Information
Website
www.palvellatx.comCorporate Office
- 125 Strafford Avenue
- Suite 360
- Wayne, PA 19087
- United States
Corporate Office
- 125 Strafford Avenue
- Suite 360
- Wayne, PA 19087
- United States
Palvella Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. PIPE | 24-Jul-2024 | $78.9M | Announced | Generating Revenue | ||
| 7. Reverse Merger | 24-Jul-2024 | Announced | Generating Revenue | |||
| 6. Later Stage VC (Series D) | 05-Jan-2023 | Completed | Clinical Trials - General | |||
| 5. Later Stage VC (Series C) | 28-May-2020 | Completed | Clinical Trials - General | |||
| 4. Early Stage VC (Series B) | 12-Aug-2019 | Completed | Clinical Trials - General | |||
| 3. Corporate | 18-Dec-2018 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 14-Jun-2018 | $4.44M | $4.44M | Completed | Startup | |
| 1. Grant | Completed | Startup |
Palvella Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A-2 | 1,240,134 | $0.000010 | $1.64 | $1.64 | 1x | $1.64 | 4.76% | |
| Series A-1 | 2,241,903 | $0.000010 | $1.31 | $1.31 | 1x | $1.31 | 8.61% |
Palvella Therapeutics Comparisons
Industry
Financing
Details
Palvella Therapeutics Competitors (52)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Cogent Biosciences | Formerly VC-backed | Waltham, MA | ||||
| Turning Point Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Mabworks Biotech | Private Equity-Backed | Beijing, China | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
Palvella Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Palvella Therapeutics Patents
Palvella Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4401730-A1 | Compositions of rapamycin and their use in the treatment of microcystic lymphatic malformation | Pending | 15-Sep-2021 | ||
| US-20230113775-A1 | Anhydrous compositions of egfr inhibitors and methods of use | Inactive | 10-Sep-2021 | ||
| AU-2022300265-A1 | Methods and compositions for treating gorlin syndrome | Pending | 21-Jun-2021 | ||
| EP-4358955-A1 | Methods and compositions for treating gorlin syndrome | Pending | 21-Jun-2021 | ||
| US-20240293378-A1 | Methods and compositions for treating gorlin syndrome | Pending | 21-Jun-2021 | A61K31/436 |
Palvella Therapeutics Executive Team (6)
| Name | Title | Board Seat |
|---|---|---|
| Wesley Kaupinen | Founder, President, Chief Executive Officer & Board Member | |
| Kathleen McGowan | Chief Financial Officer & Vice President of Finance and Operations | |
| Kathleen Goin | Chief Operating Officer | |
| Braham Shroot Ph.D | Chief Scientific Officer |
Palvella Therapeutics Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Aditya Asokan Ph.D | Samsara BioCapital | Board Member | |
| Cory Freedland Ph.D | Samsara BioCapital | Board Member | |
| David Tierney MD | Self | Board Member | |
| George Jenkins | Self | Chairman | |
| John Doux MD | Self | Board Member |
Palvella Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Palvella Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Adams Street Partners | PE/Buyout | Minority | ||
| CAM Capital | Family Office | Minority | ||
| Opaleye | Hedge Fund | Minority | ||
| Ligand Pharmaceuticals | Corporation | Minority | ||
| Charlottesville Angel Network | Angel Group | Minority |
Palvella Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pieris Pharmaceuticals | 24-Jul-2024 | Drug Discovery |
Palvella Therapeutics FAQs
-
When was Palvella Therapeutics founded?
Palvella Therapeutics was founded in 2015.
-
Who is the founder of Palvella Therapeutics?
Wesley Kaupinen is the founder of Palvella Therapeutics.
-
Who is the CEO of Palvella Therapeutics?
Wesley Kaupinen is the CEO of Palvella Therapeutics.
-
Where is Palvella Therapeutics headquartered?
Palvella Therapeutics is headquartered in Wayne, PA.
-
What is the size of Palvella Therapeutics?
Palvella Therapeutics has 17 total employees.
-
What industry is Palvella Therapeutics in?
Palvella Therapeutics’s primary industry is Drug Discovery.
-
Is Palvella Therapeutics a private or public company?
Palvella Therapeutics is a Private company.
-
What is Palvella Therapeutics’s current revenue?
The current revenue for Palvella Therapeutics is .
-
How much funding has Palvella Therapeutics raised over time?
Palvella Therapeutics has raised $181M.
-
Who are Palvella Therapeutics’s investors?
Adams Street Partners, CAM Capital, Opaleye, Ligand Pharmaceuticals, and Charlottesville Angel Network are 5 of 6 investors who have invested in Palvella Therapeutics.
-
Who are Palvella Therapeutics’s competitors?
NexImmune, Cogent Biosciences, Turning Point Therapeutics, Mabworks Biotech, and CytomX Therapeutics are some of the 52 competitors of Palvella Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
